



Samuel H. Pepkowitz, MD, Medical Director 345 Oyster Point Blvd South San Francisco, CA 94080 - Tel: (800) 777-0177

Patient Name DOB			DOB	Patient ID/Medical Record #	Gender	Monogram Accession #	
Date Collected Date Received			Date Received	Date Reported	Mode	Report Status	
Referring Physician				Reference Lab ID/Order #			
Comments					HIV-1 Subtyp	e: B	
NRTI	Generic Name	Brand Name	Assessment	Drug Resistance Associated Mutations Detected Comments			
	Abacavir	Ziagen	Sensitive	D67N, M184I/V			
	Didanosine	Videx	Resistant	D67N, M184I/V			
	Emtricitabine	Emtriva	Resistant	D67N, M184I/V			
	Lamivudine	 Epivir	Resistant	D67N, M184I/V			
	Stavudine	Zerit	Sensitive	D67N			
	Tenofovir	Viread	Sensitive	D67N			
	Zidovudine	Retrovir	Sensitive	D67N			
				K402N K220T			
NNRTI	Efavirenz	Sustiva	Resistant	K103N, K238T			
	Etravirine	Intelence	Sensitive	K238T			
	Nevirapine	Viramune	Resistant	K103N, K238T			
	Rilpivirine	Edurant	Sensitive	K238T			
	Dolutegravir	Tivicay	Sensitive	T97A, Y143R			
Z	Elvitegravir	 Elvitegravir	Resistant	T97A, Y143R			
_	Raltegravir	Isentress	Resistant	T97A, Y143R			
			Desigt was Describe	K20I, E35D, M36I, L90M			
П	Atazanavir	Reyataz	Resistance Possible	K20I, E35D, M36I, L90M			
		Reyataz / r‡	Sensitive	L90M			
	Darunavir	Prezista / r‡	Sensitive	E35D, L90M			
	Fosamprenavi		Sensitive	K20I, M36I, A71T, L90M			
	Indinavir	Crixivan / r‡	Sensitive	K20I, A71T, L90M			
	Lopinavir	Kaletra‡	Sensitive	K20I, E35D, M36I, A71T, L90M			
	Nelfinavir	Viracept	Resistant Resistance Possible				
	Ritonavir	Norvir					
	Saquinavir	Invirase / r‡	Resistance Possible	I13V, E35D, M36I, L90M			
	Tipranavir	Aptivus / r‡	Sensitive	1.01, 2000, MOOI, 200M			






Samuel H. Pepkowitz, MD, Medical Director 345 Oyster Point Blvd South San Francisco, CA 94080 - Tel: (800) 777-0177

Patient Name	DOB	Patient ID/Medical Record #	Gender	Monogram Accession #
Date Collected	Date Received	Date Reported	Mode	Report Status

- * Assessment of drug susceptibility is based upon detected mutations and interpreted using an advanced proprietary algorithm (version 16).
- * Interpretation algorithms for ritonavir-boosted protease inhibitors appropriate for the following dosages: AMP/r 600mg/100mg BID; ATV/r 300mg/100mg QD; IDV/r 800mg/200mg BID; LPV/r 400mg/100mg BID; SQV/r 1000mg/100mg BID; TPV/r 500mg/200mg BID; and DRV/r 600mg/100mg BID.
- * Mixtures are indicated by amino acids separated by a slash. Deletions in the amino acid sequence are indicated by a ^ symbol.



Summary of Mutations Observed

RT K32Q, V35I, D67N, Q102K, K103N, I135R, C162S, Q174K, I178M, M184I/V, Q207E, R211K, K238T, V245T, A272P, T286A, V293I, E297K, Q334Y, R356K, M357V, K358R, G359S, D364N

IN V31I, V72I, T97A, L101I, V113I, S119S/T, T124A, E138D, Y143R, E157E/Q, K188R, G193E, V201I, V234L, D288N

PR I13V, I15V, Q18K, K20I, E35D, M36I, N37E, L63P, A71T, V77I, L90M, I93L

For more information on interpreting this report, please visit www.MonogramBio.com or call Customer Service at 800-777-0177 between the hours of 6:30am to 5:00pm PT Monday through Friday.

GenoSure Archive is a DNA sequencing assay that uses next-generation sequencing to analyze the protease (amino acids 1-99), reverse transcriptase (amino acids 1-400) and integrase (amino acids 1-288) coding regions derived from HIV-1 cell associated DNA. Subtype is determined using the protease and reverse transcriptase sequence information. This assay meets the standards for performance characteristics and all other quality control and assurance requirements established by the Clinical Laboratory Improvement Amendments. The results have been disclosed to you from confidential records protected by law and are not to be disclosed to unauthorized persons. Further disclosure of these results is prohibited without specific consent of the persons to whom it pertains, or as permitted by law.

Page 2 of 2